Rasagiline in treatment of Parkinson's disease

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 1 A, 2008, Pages 11-20

  Nayak, Lakshmi ^a   Henchcliffe, Claire ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Monoamine oxidase inhibitor; Parkinson's disease; Propargylamine; Rasagiline

Indexed keywords

ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE; SELEGILINE; TEVA; TEVA EISAI; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANOREXIA; ARTICLE; ASTHENIA; BLOOD PRESSURE; CLINICAL TRIAL; CONFUSION; DELIRIUM; DEPRESSION; DIZZINESS; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FOOD; HALLUCINATION; HEADACHE; HUMAN; HYPOTENSION; INFECTION; INSOMNIA; MELANOMA; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; TREATMENT OUTCOME; VOMITING;

EID: 41549092261     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Akao Y, Maruyama W, Yi H, et al 2002. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett, 326:105-8.
2. Biglan KM, Ravina B. 2007. Neuroprotection in Parkinson's disease:an elusive goal. Semin Neurol, 27:106-12.
3. Blackwell B. 1991. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol, 11:55-9.
4. Blandini F, Armentero MT, Fancellu R, et al 2004. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol, 187:455-9.
5. Braak H, Del Tredici K, Rub U, et al. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24:197-211.
6. Chen JJ, Swope DM. 2005. Clinical pharmacology of rasagiline:a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol, 45:878-94.
7. Collins GG, Sandler M, Williams ED, et al. 1970. Multiple forms of human brain mitochondrial monoamine oxidase. Nature, 225:817-20.
8. Demarcaida JA, Schwid SR, White WB, et al. 2006. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord, 21:1716-21.
9. Elmer L, Schwid S, Eberly S, et al. 2006. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci, 248:78-83.
10. Falm S. 2003. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci, 991:1-14.
11. Fiala K-H, Whetteckey J, Manyam BV. 2003. Malignant melanoma and levodopa in Parkinson's disease:causality or coincidence? Parkinsonism Relat Disord, 9:321-7.
12. Finberg JP, Lamensdorf I, Commissiong JW, et al. 1996. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl, 48:95-101.
13. Finberg JP, Takeshima T, Johnston JM, et al. 1998. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport, 9:703-7.
14. Finberg JP, Wang J, Bankiewicz K, et al. 1998. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl, 52:279-85.
15. Fowler JS, Volkow ND, Logan J, et al. 1994. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse, 18:86-93.
16. Freedman N, Mishani E, Krausz Y, et al. 2005. In vivo measurement of brain monoamine oxidase B (MAO-B activity after rasagiline treatment, using L-[11C]Deprenyl and positron emission tomography (PET). Movement Disorders, S89:P298.
17. Goetz CG, Schwid SR, Eberly SW, et al. 2006. Safety of rasagiline in elderly patients with Parkinson disease. Neuroloy, 66:1427-9.
18. Goggi J, Theofilopoulos S, Riaz SS, et al. 2000. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport, 11:3937-41.
19. Green AR, Mitchell BD, Tordoff AF, et al. 1977. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol, 60:343-9.
20. Hirsch EC, Hunot S, Faucheux B, et al. 1999. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord, 14:383-5.
21. Hung AY, Schwarzschild MA. 2007. Clinical trials for neuroprotection in Parkinson's disease:overcoming angst and futility? Curr Opin Neurol, 20:477-83.
22. Kamakura K, Mochizuki H, Kaida Y, et al. 2004. Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline. Parkinsonism Relat Disord, 10:235-42.
23. Lang AE. 2007. The progression of Parkinson disease:a hypothesis. Neurology, 68:948-52.
24. Lang AE, Obeso JA. 2004. Challenges in Parkinson's disease:restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol, 3:309-16.
25. Lauterbach EC. 2004. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am, 27:801-25.
26. Lewitt PA. 2006. Neuroprotection for Parkinson's disease. J Neural Transm Suppl, 113-22.
27. Mandel S, Weinreb O, Amit T, et al. 2005. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev, 48:379-87.
28. Maruyama W, Akao Y, Carrillo MC, et al. 2002. Neuroprotection by propargylamines in Parkinson's disease:suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol, 24:675-82.
29. Maruyama W, Akao Y, Youdim MB, et al. 2001. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem, 79:727-35.
30. Maruyama W, Nitta A, Shamoto-Nagai M, et al. 2004. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int, 44:393-400.
31. Montastruc JL, Chaumerliac C, Desboeuf Y, et al. 2000. Adverse drug reactions to selegiline:a review of the French pharmacovigilance database. Clin Neuropharmacol, 23:271-5.
32. Naoi M, Maruyama W, Akao Y, et al. 2006. Involvement of type A monoamine oxidase in neurodegeneration:regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm Suppl, 67-77.
33. O'Carroll AM, Fowler CJ, Phillips JP, et al. 1993. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol, 322:198-202.
34. Olanow CW. 2006. Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology, 66:S69-79.
35. Parkinson Study Group. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med, 321:1364-71.
36. Parkinson Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med, 328:176-83.
37. Parkinson Study Group 2002. A controlled trial of rasagiline in early Parkinson disease:the TEMPO Study. Arch Neurol, 59:1937-43.
38. Parkinson Study Group. 2004. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol, 61:561-6.
39. Parkinson Study Group. 2005. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations:the PRESTO study. Arch Neurol, 62:241-8.
40. Rabey JM, Sagi I, Huberman M, et al. 2000. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease:a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol, 23:324-30.
41. Rascol O, Brooks DJ, Melamed E, et al. 2005. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet, 365:947-54.
42. Richard IH, Kurlan R, Tanner C, et al, 1997. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology, 48:1070-7.
43. Riederer P, Lachenmayer L, Laux G. 2004. Clinical applications of MAO-Inhibitors. Curr Med Chem, 11:2033-43.
44. Riederer P, Youdim MB. 1986. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J Neurochem, 46:1359-65.
45. Ritter JL, Alexander B. 1997. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry, 9:7-13.
46. Shults CW. 2003. Treatments of Parkinson disease: circa 2003. Arch Neurol, 60:1680-4.
47. Speiser Z, Levy R, Cohen S. 1998. Effects of N-propargyl-1-(R)ammoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl, 52:287-300.
48. Squires RF. 1972. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv Biochem Psychopharmacol, 5:355-70.
49. Stem MB, Marek KL, Friedman J, et al. 2004. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord, 19:916-23.
50. Sternbach H. 1991. The serotonin syndrome. Am J Psychiatry, 148:705-13.
51. Suchowersky O, Devries J. 1990. Possible interactions between deprenyl and prozac. Can J Neurol Sci, 17:352-3.
52. Tanner CM. 2000. Dopamine agonists in early therapy for Parkinson disease: promise and problems. Jama, 284:1971-3.
53. Thebault JJ, Guillaume M, Levy R. 2004. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline:a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy, 24:1295-305.
54. Toyama SC, Iacono RP. 1994. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother, 28:405-6.
55. Waters CH. 1994. Fluoxetine and selegiline - lack of significant interaction. Can J Neurol Sci, 21:259-61.
56. Weinreb O, Amit T, Bar-Am O, et al. 2005. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci, 1053:348-55.
57. Yi H, Maruyama W, Akao Y, et al. 2006. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm, 113:21-32.
58. Youdim MB. 1995. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr Scand Suppl, 386:5-7.
59. Youdim MB, Bar Am O, Yogev-Falach M, et al. 2005. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res, 79:172-9.
60. Youdim MB, Gross A, Finberg JP. 2001. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol, 132:500-6.
61. Youdim MB, Riederer PF 2004. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology, 63:S32-5.
62. Youdim MB, Tipton KF 2002. Rat striatal monoamine oxidase-B inhibition by 1-deprenyl and rasagiline:its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat Disord, 8:247-53.
63. Youdim MB, Wadia A, Tatton W, et al. 2001. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci, 939:450-8.
64. Youdim MB, Weinstock M 2001. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol, 21:555-73.